Anticarin- β shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis

Anticarin-β 通过特异性抑制 CCT4 来损害蛋白质稳态,显示出良好的抗骨肉瘤作用

阅读:3
作者:Gan Wang, Min Zhang, Ping Meng, Chengbo Long, Xiaodong Luo, Xingwei Yang, Yunfei Wang, Zhiye Zhang, James Mwangi, Peter Muiruri Kamau, Zhi Dai, Zunfu Ke, Yi Zhang, Wenlin Chen, Xudong Zhao, Fei Ge, Qiumin Lv, Mingqiang Rong, Dongsheng Li, Yang Jin, Xia Sheng, Ren Lai

Abstract

Unlike healthy, non-transformed cells, the proteostasis network of cancer cells is taxed to produce proteins involved in tumor development. Cancer cells have a higher dependency on molecular chaperones to maintain proteostasis. The chaperonin T-complex protein ring complex (TRiC) contains eight paralogous subunits (CCT1-8), and assists the folding of as many as 10% of cytosolic proteome. TRiC is essential for the progression of some cancers, but the roles of TRiC subunits in osteosarcoma remain to be explored. Here, we show that CCT4/TRiC is significantly correlated in human osteosarcoma, and plays a critical role in osteosarcoma cell survival. We identify a compound anticarin-β that can specifically bind to and inhibit CCT4. Anticarin-β shows higher selectivity in cancer cells than in normal cells. Mechanistically, anticarin-β potently impedes CCT4-mediated STAT3 maturation. Anticarin-β displays remarkable antitumor efficacy in orthotopic and patient-derived xenograft models of osteosarcoma. Collectively, our data uncover a key role of CCT4 in osteosarcoma, and propose a promising treatment strategy for osteosarcoma by disrupting CCT4 and proteostasis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。